logo

For the Inventor, By the Inventor

Ulm, Germany

Ratiopharm Gmbh

Calculating rank
USPTO Granted Patents = 52

% Expired Patents = 78.8



Forward Citations = 46

Loading Chart...
Loading Chart...

88 inventors (with patents filed for the assignee):

goldMedal Wolfgang Albrecht (16 out of 44 patents)

silverMedal Sebastian Rabe (8 out of 9 patents)

bronzeMedal Richard Guserle (8 out of 8 patents)

4.  Sandra Brueck (7 out of 7 patents)

5.  Roland Selig (6 out of 13 patents)

6.  Jens Geier (6 out of 6 patents)

7.  Annemarie Maier (5 out of 5 patents)

8.  Dominique Meergans (5 out of 5 patents)

9.  Jana Paetz (5 out of 5 patents)

10.  Frank Lehmann (4 out of 4 patents)

11.  Julia Schulze Nahrup (4 out of 4 patents)

12.  Katrin Rimkus (4 out of 4 patents)

13.  Frank Muskulus (4 out of 4 patents)

14.  Heinz Lubenau (3 out of 15 patents)

15.  Ganesh Vinayak Gat (3 out of 10 patents)


Core Competencies:
Ibrutinib
Palbociclib
Sofosbuvir
Dolutegravir
G-CSF
Prasugrel
Rizatriptan
Tadalafil
Ezetimibe
Lopinavir
Ticagrelor
Deferasirox

52 patents:

1. 10669275 - Methods of preparing co-crystals of ibrutinib with carboxylic acids (2020-06-02),
2. 10526326 - Crystalline form and acetic acid adducts of palbociclib (2020-01-07),
3. 10464903 - Process for preparing quinolin-2-yl-phenylamine derivatives and their salts (2019-11-05),
4. 10377758 - Co-crystals of ibrutinib with carboxylic acids (2019-08-13),
5. 10214553 - Solid state forms of sofosbuvir (2019-02-26),
6. 10059715 - Acid addition salt of ibrutinib (2018-08-28),
7. 9969674 - MMF-derivatives of ethyleneglycols (2018-05-15),
8. 9868690 - Prodrugs of monomethyl fumarate (MMF) (2018-01-16),
9. 9856270 - Dolutegravir salts (2018-01-02),
10. 9796659 - Derivatives of polyhydroxy compounds (2017-10-24),
11. 9663480 - BIS-MMF derivatives (2017-05-30),
12. 9593068 - Derivatives of tartaric acid (2017-03-14),
13. 9567289 - Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds (2017-02-14),
14. 9480755 - Pharmaceutical composition comprising dapagliflozin and cyclodextrin (2016-11-01),
15. 9480655 - Solid pharmaceutical dosage form of dolutegravir (2016-11-01),
Company Overview
Ratiopharm GmbH, headquartered in Ulm, Germany, specializes in the development and manufacturing of pharmaceutical formulations. The company focuses on a diverse range of therapeutic areas, including oncology and infectious diseases, with notable expertise in compounds such as Ibrutinib, Palbociclib, and Sofosbuvir. Ratiopharm is committed to advancing healthcare through innovative drug solutions, leveraging its knowledge in key technologies like G-CSF and Dolutegravir to address critical medical needs globally.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

Ratiopharm Gmbh USPTO Patent Assignee Logo
52 Patents

#4 in Ulm

#1,024 in Germany

#13,579 in the World

Ulm, DE
Ulm, Germany

Ratiopharm Gmbh

Forward Citations = 46

88 inventors:

goldMedal Wolfgang Albrecht (16 out of 44 patents)

silverMedal Sebastian Rabe (8 out of 9 patents)

bronzeMedal Richard Guserle (8 out of 8 patents)

4.  Sandra Brueck (7 out of 7 patents)

5.  Roland Selig (6 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ratiopharm Gmbh. Retrieved from https://idiyas.com/company/ratiopharm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…